SBRT for Oligoprogressive NSCLC After First Line Treatment With Immune Checkpoint Inhibitors
Clinical trial NCT05387044 · UNKNOWN
Trial details
- NCT number
- NCT05387044
- Sponsor
- Zhejiang Cancer Hospital
- Status
- UNKNOWN
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2022-05-01
- Primary completion
- 2023-04-30
- Enrollment
- 28
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.